Latent reservoirs for HIV-1

Current Opinion in Infectious Diseases

Volumn 12, Issue 1, 1999, Pages 5-11

  Blankson, Joel ^a   Persaud, Deborah ^a   Siliciano, Robert F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; PROTEINASE INHIBITOR; ZIDOVUDINE;

DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; MEMORY CELL; NONHUMAN; PERSISTENT VIRUS INFECTION; REVIEW; T LYMPHOCYTE; VIREMIA; VIRUS REPLICATION;

EID: 0033012365     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199902000-00002     Document Type: Review

References (54)

1. Garcia-Blanco MA, Cullen BR. Molecular basis of latency in pathogenic human viruses. Science 1991; 254:815-820
2. Stevenson M. Molecular mechanisms for the regulation of HIV replication, • persistence and latency AIDS 1997, 11(Suppl. A):S25-S33. A thorough and thoughtful review of earlier work on viral persistence is presented.
3. Schrager LK, D'Souza PM Cellular and anatomical reservoirs of HIV-1 in • patients receiving potent antiretroviral combination therapy. JAMA 1998; 280:67-71 This is an excellent review of the various types of reservoirs in which HIV can persist.
4. Finzi D, Siliciano RF. Viral dynamics in HIV-1 infection. Cell 1998; 93.665-671. • A review covering the inrtial work on the current dynamic model for viral replication in infected individuals and the latent reservoir of HIV-1.
5. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
6. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373:117-122.
7. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay •• characteristics of HIV-1-infected compartments during combination therapy. Nature 1997; 387.188-191. An important work that defines that first and second phase of decay of plasma virus in patients on combination therapy. This paper laid the groundwork for rational analysis of the possibility of eradicating HIV-1 infection with antiretroviral drugs
8. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. •• Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739. This is landmark paper demonstrating a reduction of plasma virus to undetectable levels in a substantial fraction of patients starting on combination therapy.
9. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier J, et •• al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team N Engl J Med 1997, 337:725-733. This is landmark paper demonstrating a reduction of plasma virus to undetectable levels in a substantial fraction of patients starting on combination therapy
10. Heath SL, Tew JG, Szakal AK, Burton GF Follicular dendritic cells and human immunodeficiency virus infectivity. Nature 1995; 377:7440-744
11. Burton GF, Masuda A, Heath SL, Smith BA, Tew JG, Szakal AK Follicular dendritic cells (FDC) in retroviral infection, host/pathogen perspectives. Immuno Rev 199, 156:185-197.
12. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard • K, et al Kinetics of response in lymphoid tissue to antiretroviral therapy of HIV-1 infection. Science 1997; An important paper describing the decay of infected cells and extracellular virus reservoirs in the peripheral lymphoid organs of patients on combination therapy.
13. Ho DD, Rota TR, Hirsh MS Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest 1986; 77:1712-1720.
14. Nicolson JKA, Gross GD, Callaway CS, McDougal JS. In vitro infection of human monocytes with T lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). J Immunol 1986; 137:323-329.
15. Van Furth R. Origin and turnover of monocytes and macrophages Curr Top Pathol 1989; 79:125-150.
16. Sierra-Madero JC, Toossi Z, Hom DL, Finegan CK, Hoenig E, Rich EA. Relationship between load of virus in alveolar macrophages from human immunodeficiency virus type 1-infected persons, production of cytokines, and clinical status. J Infect Dis 1994; 169:18-27.
17. Mcilroy D, Autran B, Cheynier R, Clauvel JP, Oksenhendler E, Debre P, Hosmalin A Low infection frequency of macrophages in the spleens of HIV+ patients. Res Virol 1996, 147:115-121.
18. + T-cells with integrated HIV-1 DNA are present at similar low frequencies in the blood and lymph nodes of patients on combination therapy.
19. Glass JD, Johnson RT Human immunodeficiency virus and the brain. Ann Rev • Neurosci. 1996; 19:1-26. An excellent review of neurologic aspects of HIV-1 infection.
20. Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 in semen, an isolated virus reservoir [letter]. Lancet 1997.Oct 18 350:1141
21. Kiessling AA, Fitzgerald LM, Zhang D, Chhay H, Brettler D, Eyre RC, et al. Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Research.& Human Retroviruses 1998, 14 Suppl 1:S33-S41.
22. Zhang H, Dornadula G, Beumont M, Livornese L, Van Uitert B, Henning K, • Pomerantz RJ. HIV-1 in the semen of men receiving highly active anti-retroviral therapy. N Engl J Med 1998; in press. The persistence of replication competent virus in cells in the seminal fluid is documented in a small number of men who were aviremic on combination therapy. Although the paper does not deal with transmission of virus, the implications are clear.
23. + T-cells with integrated HIV-1 DNA in infected individuals.
24. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure Cell 1990; 61:213-222.
25. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991; 254:423-427.
26. Spina CA, Guatelli JC, Richman DD Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995; 69:2977-2988.
27. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression, a molecular model for latency Cell 1990; 61:1271-1276.
28. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T-cells. Nature 1987; 326:711-713.
29. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long-terminal repeat. Proc Natl Acad Sci U S A 1989; 86:5974-5978.
30. Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci USA 1989; 86:2365-2368.
31. Michael NL, Morrow P, Mosca J, Vahey M, Burke DS, Redfield RR. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns J Virol 1991; 65:7084-7084.
32. Seshamma T, Bagasra O, Trono D, Baltimore D, Pomerantz RJ Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1992; 89:10663-10667.
33. Embretson J, Zupancic M, Ribas JL, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-362.
34. + T-cells in patients who were aviremic on combination therapy
35. + T-cells in patients who were aviremio on combination therapy.
36. + T-cells in patients who were aviremic on combination therapy.
37. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo virion clearance rate, infected cell life-span, viral generation time. Science 1996; 271.1582-1586
38. Vila J, Nugier F, Bargues G, Vallet T, Peyramond D, Hamedisangsan F, Seigneurin JM Absence of viral rebound after treatment of HIV-infected patients with didanosme and hydroxycarbamide. Lancet 1997; 350:635-636.
39. Pialoux G, Rafti F, Brun-Vezinet R, Meiffred YV, Flandre P, Gastaut JA, et al. • Trilege study team: A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously treated patients N Engl J Med 1998; 338:1269-1276. An important study demonstrating incomplete suppression of viral replication in a subset of patients who were switched to less intense 'maintenance therapy' following induction with triple drug therapy
40. •].
41. •] demonstrating incomplete suppression of viral replication in a subset of patients who were switched to less intense 'maintenance therapy' following induction with triple drug therapy.
42. Burman WJ, Reves RR, Cohn DL. The case for conservative management of • early HIV disease. JAMA 1998; 280:93-95. A thoughtful commentary on the problems associated with aggressive antiretroviral therapy.
43. Walker BD, Basgoz N. Treat HIV-1 infection like other infections-treat it. JAMA • 1998; 280:91-92. A persuasive presentation of arguments for early initiation of aggressive antiretroviral therapy.
44. Chun T-W, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early • establishment of a pool of latently infected, resting CD4+ T-cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998; 95:8869-8873 This paper demonstrates that the latent reservoir for HIV-1 is established early during primary HIV-1 infection.
45. Luzuriaga K, Bryuson Y, Krogstad P, Robinson J, Stechenberg B, Lamson M, et •• al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type I infection N Engl J Med 1997; 336.1343-1349. An important report describing the results of aggressive antiretroviral therapy in children
46. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, Gallo RC. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-805.
47. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, •• Walker BD. Vigorous HIV-1-specific CD4+ T-cell responses associated with the control of viremia. Science 1997; 278:1447-1450 The authors demonstrate that helper T-cell responses to HIV-1 are absent in most infected individuals but present in some long-term non-progressors Interestingly, initiation of aggressive antiretroviral therapy during or before seroconversion preserves this component of the immune response to HIV-1. This paper provides a strong argument for early initiation of therapy and also provides key insights into the pathogenesis of immune deficiency in infected individuals.
48. Flexner C. HIV-1 protease inhibitors. N Engl J Med 1998, 338.1281-1292. • A comprehensive review of the pharmacology of the protease inhibitors
49. Gunthard HF, Wong JK, Ignacio CC, Guatelli JC, Riggs NL, Havlir DV, •• Richman DD. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998, 72:2422-2428. This paper provides evidence for the importance of complete suppression of viral replication in preventing the emergence of drug resistant virus.
50. Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey RT, Falloon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection N Engl J Med 1995, 332:567-575.
51. Jacobson EL, Pilaro F, Smith KA. Rational interleukin 2 therapy for HIV positive individuals. Daily low doses enhance immune fuction without toxicity. Proc Natl Acad Sci U S A 1996, 93:10405-10410
52. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175:781-789.
53. Chun T-W, Engel D, Mizell SB, Ehler LA, Fauci AS. Induction of HIV-1 replication in latently infected CD4+ T-cells using a combination of cytokines. J Exp Med 1998; 188:83-91.
54. Unutmaz D, Pileri P, Abrignani S. Antigen-independent activation of naive and memory resting T-cells by a cytokine combination. J Exp Med 1994; 180:1159-1164.